Current Treatment for Hepatitis C
Hours: 1.00
Worldwide, about 71 million people are infected with the hepatitis C virus (HCV) (Saracco et al., 2022). In the U.S., it is estimated that 57,500 people are affected by acute HCV annually, and about 2.4 million people have chronic HCV (CDC, 2020a; 2021a). The World Health Organization (WHO) have endorsed a global strategy to eradicate HCV by 2030 (Saracco et al., 2022). Over the past several years, new classes of medications have been developed that are both highly effective and tolerable, allowing substantially more patients to achieve a cure for this disease. Healthcare providers (HCPs) should have knowledge of treatment modalities for patients who have HCV.
The goal of this course is to provide nursing professionals, pharmaceutical professionals, and physicians in acute care with guidance on the disease course and management of patients with HCV, who are treatment-naïve without cirrhosis or who have compensated cirrhosis.
Worldwide, about 71 million people are infected with the hepatitis C virus (HCV) (Saracco et al., 2022). In the U.S., it is estimated that 57,500 people are affected by acute HCV annually, and about 2.4 million people have chronic HCV (CDC, 2020a; 2021a). The World Health Organization (WHO) have endorsed a global strategy to eradicate HCV by 2030 (Saracco et al., 2022). Over the past several years, new classes of medications have been developed that are both highly effective and tolerable, allowing substantially more patients to achieve a cure for this disease. Healthcare providers (HCPs) should have knowledge of treatment modalities for patients who have HCV. The goal of this course is to provide nursing professionals, pharmaceutical professionals, and physicians in acute care with guidance on the disease course and management of patients with HCV, who are treatment-naïve without cirrhosis or who have compensated cirrhosis.
District of Columbia Board of Nursing
District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Nurses will receive 1.00 contact hours for participating in this course.
Florida Board of Nursing
Florida Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
American Nurses Credentialing Center
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses will receive 1.00 Nursing Contact Hours after successfully completing this course.
Georgia Board of Nursing
Georgia Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Accreditation Council for Continuing Medical Education
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Relias LLC designates this enduring activity for a maximum of 1.00 AMA PRA category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
South Carolina Board of Nursing
South Carolina Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Florida Board of Medicine
Florida Board of Medicine (CEBroker Provider #50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
West Virginia Board of Registered Nursing
West Virginia Board of Registered Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
New Mexico Board of Nursing
New Mexico Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Arkansas State Board of Nursing
Arkansas State Board Of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Nurses will receive 1.00 contact hours for participating in this course.
Ohio State Medical Board
State Medical Board of Ohio (CEBroker Provider #: 50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
Louisiana State Board of Medical Examiners
Louisiana State Board of Medical Examiners (CEBroker Provider #: 50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
Mississippi State Board of Medical Licensure
Mississippi State Board of Medical Licensure (CEBroker Provider #: 50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
Kentucky Board of Nursing
Kentucky Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Mississippi Board of Nursing
Mississippi Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
North Dakota Board of Nursing
North Dakota Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
New Mexico Medical Board
Physicians will receive 1.00 AMA PRA category 1 Credits™.
South Carolina Board of Medical Examiners
South Carolina Board of Medical Examiners (CEBroker Provider #50-290)
Tennessee Board Of Medical Examiners
Tennessee Board of Medical Examiners (CEBroker Provider #50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™
Michigan Board of Nursing
Michigan Board of Medicine
Physicians will receive 1.00 AMA PRA category 1 Credits™.
Accreditation Council for Pharmacy Education
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Type Activity: [Custom_Code]
Target Audience Designation: [Custom_Code2]
ACPE Universal Activity Number: JA4008266-0000-22-037-H01-P
Florida Board of Pharmacy
Florida Board of Pharmacy (CEBroker Provider #50-290)
This module is approved for 1.00 contact hours.
Michigan Board of Pharmacy
Michigan Board of Pharmacy (CEBroker Provider #50-290)
This module is approved for 1.00 contact hours.
Outline:
Section 1: Introduction
About This Course
Learning Objectives
Section 2: Epidemiology and Pathophysiology
Overview
Genotypes
HCV Phases
HCV Progression
Section 3: Screening, Staging, and Clinical Presentations
Screening and Diagnosis
Clinical Presentations
Fibrosis Staging
Cirrhosis Compensation
Section 4: Management of HCV
HCV Lifecycle
Direct-Acting Antivirals (DAAs)
Management for Treatment-Naïve Patients
Patient Monitoring and Follow-Up
Treatment Lapses
Cost Considerations
Barriers to HCV Treatment
Section 5: Ongoing Patient Care
Care Coordination
Cirrhosis Complications
Section 6: Clinical Vignette
Meet Joe
Section 7: Conclusion
Course Summary
Course Contributor
Resources
References
Alia Lutz, BSN, RN, has over 10 years of experience as a Registered Nurse with a focus on cardiothoracic, respiratory, and coronary care. She has also had experience in Med-Surg, step-down and ICU. Prior to joining Relias as a SME and Content Writer for acute care, she provided virtual education and injection training on injectable biologics to patients, reported adverse events, and was a patient advocate. She has collaborated with peers on creating job aids, writing policies, and improving quality of care and documentation. Alia received her Bachelors in Nursing from Otago Polytechnic in New Zealand in 2011. Disclosure: Alia Lutz, BSN, RN has no Relevant Financial or Non-Financial Relationship with ineligible companies to disclose.
The target audience for this course is: Nurses; Pharmacists; Physicians; in the following settings: Acute Care Facility.
Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
If you require special accommodations to complete this module, please contact Relias Customer Support here.
